Alembic Pharmaceuticals Ltd. benchmarking: Perfomance to industry peers

Financial

	Alembic Pharma	Jubilant Pharmova	Caplin Point Lab
Operational Metrics
Pharmaceuticals
US DMF Filings	140.0 .	98.0 .	n/a
Number of ANDA's Filed in USA	268.0 .	100.0 .	51.0 .
Number of ANDA's Approved By USFDA	223.0 .	62.0 .	38.0 .
Number of ANDA's Filed in Latam	14.0	n/a	n/a
Number of ANDA's Approved by Latam	4.0	n/a	n/a
Number of ANDA's Filed in South Africa	21.0	n/a	n/a
Number of ANDA's Approved by South Africa	7.0	n/a	n/a
Number of ANDA's Filed in Australia	17.0	n/a	n/a
Number of ANDA's Approved by Australia	14.0	n/a	n/a
Number of ANDA's Filed in Canada	21.0	24.0	n/a
Number of ANDA's Approved by Canada	20.0	24.0	n/a
Number of ANDA's Filed in Europe	21.0	38.0	n/a
Number of ANDA's Approved in Europe	19.0	37.0	n/a
R&D as a % of Total Sales	8.0 %	0.18 %	3.52 %
Financials
5 yr Average ROE	12.89 %	7.82 %	19.84 %
5yr average Equity Multiplier	1.39	1.96	1.15
5yr Average Asset Turnover Ratio	0.86	0.61	0.68
5yr Avg Net Profit Margin	11.15 %	6.45 %	25.35 %
Price to Book	3.41	2.71	4.65
P/E	28.56	37.44	24.94
5yr Avg Cash Conversion Cycle	9.46 Days	-39.98 Days	70.68 Days
Inventory Days	99.1 Days	74.06 Days	66.07 Days
Days Receivable	66.32 Days	45.59 Days	110.7 Days
Days Payable	164.9 Days	149.89 Days	85.23 Days
5yr Average Interest Coverage Ratio	30.59	3.78	633.04
5yr Avg ROCE	15.26 %	8.15 %	24.45 %
5yr Avg Operating Profit Margin	17.29 %	16.76 %	31.52 %
5 yr average Debt to Equity	0.14	0.55	0.0
5yr CAGR Net Profit	-12.64 %	0.08 %	17.23 %
5yr Average Return on Assets	9.32 %	4.12 %	17.23 %
Shareholdings
Promoter Holding	69.74 %	47.68 %	70.57 %
Share Pledged by Promoters	0.0	5.4 %	0.0
Change in Promoter Holding (3 Yrs)	0.13 %	-3.0 %	1.69 %
Change in Mutual Fund Holding (3 Yrs)	3.19 %	6.74 %	0.74 %

Business

	Alembic Pharma	Jubilant Pharmova	Caplin Point Lab
Product Wise Break-Up	Product Wise Break-Up Formulations 84.75 Active Pharmaceutical Ingredient (API) 15.25 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Branded Generic 0 Generic 0	Product Wise Break-Up Radiopharmaceuticals 46.89 Specialty intermediates 0 Solid dosage formulations 8.71 India branded pharmaceuticals 0.7 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 7.91 Contract Research and Development Services 7.87 Branded Generic 0 Nutritional products 0 Contract Manufacturing 17.66 Formulations 0 Generic 0 Active Pharmaceutical Ingredient (API) 0 Anti-allergic 9.75 Others 0.51	Product Wise Break-Up Radiopharmaceuticals 0 Specialty intermediates 0 Solid dosage formulations 0 India Branded pharmaceuticals 0 Life science chemicals 0 Active pharmaceutical ingredients 0 0 Branded Generics 25.0 Nutritional products 0 0 Formulations 0 Formulations 75.0 Active Pharmaceutical Ingredient (API) 0 Allergy therapy products 0
Product Wise Break-Up	Product Wise Break-Up Formulations 84.75 Active Pharmaceutical Ingredient (API) 15.25 0 Radiopharmaceuticals 0 Allergy therapy products 0 Active pharmaceutical ingredients 0 India Branded pharmaceuticals 0 Nutritional products 0 Specialty intermediates 0 Life science chemicals 0 0 Solid dosage formulations 0 Branded Generic 0 Generic 0	Product Wise Break-Up Radiopharmaceuticals 46.89 Specialty intermediates 0 Solid dosage formulations 8.71 India branded pharmaceuticals 0.7 Life science chemicals 0 Active Pharmaceutical Ingredient (API) 7.91 Contract Research and Development Services 7.87 Branded Generic 0 Nutritional products 0 Contract Manufacturing 17.66 Formulations 0 Generic 0 Active Pharmaceutical Ingredient (API) 0 Anti-allergic 9.75 Others 0.51	Product Wise Break-Up Radiopharmaceuticals 0 Specialty intermediates 0 Solid dosage formulations 0 India Branded pharmaceuticals 0 Life science chemicals 0 Active pharmaceutical ingredients 0 0 Branded Generics 25.0 Nutritional products 0 0 Formulations 0 Formulations 75.0 Active Pharmaceutical Ingredient (API) 0 Allergy therapy products 0
Location Wise Break-Up	Location Wise Break-Up Rest of the World 60.76 India 39.24 China 0 Americas and Europe 0 USA 0 Africa 0 LATAM 0	Location Wise Break-Up China 0 Rest of the World 5.89 USA 0 Americas and Europe 91.35 Africa 0 LATAM 0 India 2.76	Location Wise Break-Up China 0 Rest of the World 0 USA 18.0 Americas and Europe 0 Africa 6.0 Latin America 76.0 India 0
Therapeutic Area Break-Up	Therapeutic Area Break-Up Others 100	-	-

Alembic Pharmaceuticals Ltd.

Alembic Pharmaceuticals Ltd.

Financial

Business

SIGN UP FOR FREE